Isodiol International Inc. (CSE:ISOL)(OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator and market leader, is pleased to announce the launch of its automated retail strategy, with the Company planning to roll out a nation-wide network of branded kiosks, which will provide consumers with convenient access to natural health and wellness cannabinoid (CBD) based products.
The initial roll-out of Isodiol’s kiosks will focus on the launch of its Iso-Sport branded products, as well as the recently launched Kathy Ireland Health & Wellness brand. As such, the Company will support its nationwide rollout through close marketing collaboration with its brand influencers to inspire, educate and connect directly with customers. The curated user interface and integrated digital signage will also ensure that the product and brand presentations remain consistent.
“Companies with early insights into new trends and norms of daily commercial behavior are poised to prosper,” said CEO of Isodiol, Marcos Agramont. “As it stands, there is a global trend and substantial increase in the deployment of interactive self-service kiosks around the world.”
The Company plans to introduce its kiosks at various high profile and high traffic locations, as well as co-locating within retailers such as pharmacies, convenient stores, wellness centers, gyms, and more. The products and locations of these units will comply with the appropriate legislation in each jurisdiction. The use of such systems will also include innovative ways to collect data on inventory and customer behavior and preferences, thus allowing better recommendations to be offered based on purchase trends, or other metrics such as a user’s input of specific health conditions.
The kiosks will have different recognition capabilities in order to verify users, as well as provide many different payment options including credit cards, debit cards, PayPal, Google Wallet, and Apple Pay. Additionally, the Company expects cryptocurrency, such as Bitcoin to be an accepted payment method in the near future.
A mobile application will also provide consumers with the ability to browse products remotely and determine in real time where to find a kiosk stocked with their desired products. The company will also seek to further harness the power of social media, integrated marketing campaigns, promos, coupons and more. For instance, the Company’s automated retail system will allow customer interaction with the ability to tweet messages directly to the kiosks, and also the ability to upload pictures to Instagram for samples or discounts.
Further, through its enterprise scale cloud based platform, the Company will be able to centrally monitor its network of automated retail units, and manage and optimize in real-time every aspect of its operations, from merchandising to remote technical support.
“In an era of growing mobility, consumers demand for easy access to products and services anytime and from anywhere,” added Agramont. “We are excited to begin a new phase of our retail strategy and significantly increase our footprint and direct access to consumers for our industry leading line of CBD products.”
The Company is also pleased to announce that it debuted its Iso-Sport vending machine at the Phoenix Europa Games, which took place August 11-12, 2018. As regulation continues to become favorable, the Company intends to place multiple vending machines in gyms and fitness centers across the globe. The Company believes this is another innovative measure to provide consumers with convenient access to natural health and wellness CBD based products around the globe.
For further information, please visit http://www.azfamily.com/story/38864802/vendor-discusses-athletes-using-cannabis-at-europa-games
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
Thoughtful Brands, Inc. (CSE:TBI)(FWB:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe, announces that it intends to consolidate its issued and outstanding common shares (“Shares”) at a ratio of ten (10) pre-consolidated Shares to one (1) post-consolidation Share (the “Consolidation
The Company currently has 389,274,701 Shares issued and outstanding. Following the Consolidation there will be approximately 38,927,470 Shares issued and outstanding. No fractional Shares will be issued and any fractions of a Share will be rounded down to the nearest whole number of Shares. The exercise or conversion price and the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted upon Consolidation.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.